Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Pazopanib appears safe in mRCC and renal failure
Masini C et al. Clin Genitourin Cancer. 2018 Oct 1. doi: 10.1016/j.clgc.2018.10.001.
Key clinical point: Pazopanib may be safe and effective for metastatic renal cell carcinoma in patients with renal failure.
Major finding: No difference was reported in the incidence of adverse events in patients with or without renal dysfunction.
Study details: A retrospective analysis of 229 metastatic renal cell carcinoma patients treated with pazopanib.
Disclosures: Editorial assistance was supported by Novartis. The authors reported no conflict of interests related to the work.
Citation:
Masini C et al. Clin Genitourin Cancer. 2018 Oct 1. doi: 10.1016/j.clgc.2018.10.001.